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Abstract
Introduction: Early risk stratification in the emergency department (ED) is vital to reduce time to effective
treatment in high-risk patients and to improve patient flow. Yet, there is a lack of investigations evaluating the
incremental usefulness of multiple biomarkers measured upon admission from distinct biological pathways for
predicting fatal outcome and high initial treatment urgency in unselected ED patients in a multicenter and
multinational setting.
Method: We included consecutive, adult, medical patients seeking ED care into this observational, cohort study in
Switzerland, France and the USA. We recorded initial clinical parameters and batch-measured prognostic biomarkers
of inflammation (pro-adrenomedullin [ProADM]), stress (copeptin) and infection (procalcitonin).
Results: During a 30-day follow-up, 331 of 7132 (4.6 %) participants reached the primary endpoint of death within
30 days. In logistic regression models adjusted for conventional risk factors available at ED admission, all three
biomarkers strongly predicted the risk of death (AUC 0.83, 0.78 and 0.75), ICU admission (AUC 0.67, 0.69 and 0.62)
and high initial triage priority (0.67, 0.66 and 0.58). For the prediction of death, ProADM significantly improved
regression models including (a) clinical information available at ED admission (AUC increase from 0.79 to 0.84), (b)
full clinical information at ED discharge (AUC increase from 0.85 to 0.88), and (c) triage information (AUC increase
from 0.67 to 0.83) (p <0.01 for each comparison). Similarly, ProADM also improved clinical models for prediction of
ICU admission and high initial treatment urgency. Results were robust in regard to predefined patient subgroups by
center, main diagnosis, presenting symptoms, age and gender.
Conclusions: Combination of clinical information with results of blood biomarkers measured upon ED admission
allows early and more adequate risk stratification in individual unselected medical ED patients. A randomized trial is
needed to answer the question whether biomarker-guided initial patient triage reduces time to initial treatment of
high-risk patients in the ED and thereby improves patient flow and clinical outcomes.
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Introduction
Emergency departments (ED) are increasingly crowded
by patients with both urgent and nonurgent health issues
[1, 2]. As a consequence, patients needing urgent care may
not be treated in time resulting in poor health outcomes
[3, 4]. Earlier risk stratification has the potential to reduce
time to effective treatment - a main predictor for patient
outcome across different medical conditions, including
septicemia [5], pneumonia [6], stroke (“time is brain”)
[7], and myocardial infarction (“time is heart”) [8]. Risk
stratification may also improve patient flow and initial
site-of-care decisions (i.e., outpatient versus inpatient
management). Hence, international guidelines recom-
mend the use of risk scores in well-defined patient
populations such as the Pneumonia Severity Index
(PSI) in community-acquired pneumonia (CAP) [9].
Yet, there is a lack of a more general risk stratification
score for undifferentiated medical patients at the most
proximal time point of seeking ED care. At this earliest
time point in ED care, risk stratification is most challenging
due to lack of thorough clinical information, but may have
the biggest potential to reduce time to effective treatment
of patients and to improve patient flow.
Several triage systems have been proposed including
the Manchester Triage System (MTS), the Australasian
Triage Scale (ATS), the Canadian Triage and Acuity
Scale (CTAS) and the Emergency Severity Index (ESI)
[10, 11]. These scores assign patients based on their pre-
senting symptoms and a combination of vital signs into
risk categories with different recommended times for
physician assessment [10]. The main rational of these
score is to stratify treatment urgency based on clinical
“red flags”. Yet, only few rigorous clinical studies have
investigated the performance of initial triage scores for
their ability to improve initial triage decisions and for
outcome prediction [10].
In addition to triage scores, there is high potential in
the use of prognostic biomarkers from distinct biological
pathways to identify persons who are at risk for high
treatment urgency and adverse medical outcome [12].
Many biomarkers have been related to risk in selected ED
patient populations, including the prognostic inflammatory
marker pro-adrenomedullin (ProADM) [13–19], the stress
marker pro-vasopressin (copeptin) [19–23] and the bacter-
ial infection marker procalcitonin (PCT) [24–27]. Measure-
ment of these biomarkers simultaneously (a “multimarker”
approach) in unselected ED patients could enhance early
risk stratification.
Herein, we evaluated the incremental usefulness of these
three previously reported prognostic biomarkers from dis-
tinct biological pathways in a large, international ED patient
cohort for predicting death, admission to the intensive care
unit (ICU) and high treatment urgency where delays in
initial treatment may have detrimental consequences.
Methods
Study design
The TRIAGE study is a multinational, prospective, ob-
servational cohort study. From March 2013 to October
2014, we included consecutive medical patients presenting
with a medical urgency at three tertiary-care hospitals
in Aarau (Switzerland), Paris (France) or Clearwater (FL,
USA), respectively. The Swiss hospital (Kantonsspital
Aarau) is a 600-bed tertiary-care hospital with most
medical admissions entering the hospital over the ED.
The French hospital (Hôpital Pitié-Salpêtrière, Paris) is a
large inner-city 1800-bed referral center. The US hospital
(Morton Plant Hospital, Clearwater, FL) is a 687-bed com-
munity referral center. As an observational quality control
study, the Institutional Review Boards (IRB) of the three
hospitals approved the study and waived the need for indi-
vidual informed consent (main Swiss IRB: Ethikkommission
Kanton Aargau (EK 2012/059); French IRB: CCTIRS -
Comité consultatif sur le traitement de l’information
en matière de recherche (C.C.T.I.R.S.), (CPP ID RCB:
2013-A00129-36); US IRB MPM-SAH Institutional Review
Board, Clearwater FL [IRB number 2013_005]). The study
was registered at the “ClinicalTrials.gov” registration
website [28] and the study protocol has been published
previously [29].
Patient sample
Patients seeking ED care for medical health issues and
meeting our inclusion criteria at one of the participating
hospital EDs were consecutively included. Inclusion cri-
teria were adult medical patients in whom an initial
blood draw was done as part of the routine ED assess-
ment. We defined “medical patient” as a patient with an
initial predominant medical health issue as judged by
the triage nurse. We excluded surgical and pediatric pa-
tients, but had no other exclusion criteria in regard to
main diagnosis or presenting symptoms to reflect the
diversity and challenges of “real life”.
Data collection
Upon ED admission, all patients were assessed by a tri-
age nurse and initial triage priority was assigned based
on the routine hospital algorithm [10]. All participating
centers categorize patients upon ED admission into tri-
age class using a triage score as part of their routine
clinical care. The Swiss center uses the German version
of the five-level MTS, which has been validated previ-
ously [30]. The US center uses the five-level Morton
Plant Hospital Triage Acuity Scale based on the French
center uses a similar five-level scoring system, which has
also been validated in France [31]. All participants pro-
vided a medical history and underwent a physical exam-
ination with measurement of vital signs and laboratory
assessment with collection of leftover blood samples.
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We also recorded the main presenting clinical symptoms
and complaints, sociodemographics and comorbidities.
Upon ED discharge, two independent attending ED phy-
sicians adjudicated a medical triage priority based on all
medical results available at this time to all patients (high
versus low triage priority). In case of disagreement, the
case was discussed with a third independent physician
until consensus was reached. All information was en-
tered into a case report form (CRF) and stored in a cen-
tralized, password-secured databank (SecuTrial).
Throughout the hospital stay, physicians, nurses and
social care workers managed patients in accordance to
hospital guidelines according to the underlying medical
condition and independent of the research team. All pa-
tients were contacted 30 days after hospital admission for
a telephone interview with a predefined questionnaire to
assess vital and functional status, hospital readmission, as
well as quality of life, care needs at home and satisfaction
with care provided.
Overall hypothesis and research aim
The overall hypothesis of this study is that the addition
of prognostic blood markers from distinct biological
pathways will improve initial clinical parameters and vital
signs for risk stratification and initial triage of patients at
an early stage of ED admission. In turn, this may translate
into better patient flow and more adequate estimation of
triage priority and site-of-care decisions.
Primary and secondary endpoints
One primary and two secondary endpoints were predefined
for inclusion in the main prediction analysis. The primary
endpoint was defined as all-cause 30-day mortality. To as-
sess vital status, we followed all patients throughout the
hospital stay and contacted them by telephone interview
30 days after admission. In case a patient could not be
reached, we contacted the family or the patient’s general
practitioner to assess vital status.
Secondary endpoints were admission to the ICU within
30 days following ED admission and high initial adjudi-
cated triage priority. The decision for ICU admission was
left to the discretion of the treating physicians. As outlined
above, initial high triage priority was adjudicated by two
independent ED physicians. Similar to a previous study,
the physicians evaluated post hoc what the real degree of
urgency (the “gold standard”) would have been, based on
all available ED data, results of diagnostic tests, and the
final diagnosis at ED discharge. Specifically, the main
question for the adjudicators was “under difficult cir-
cumstances, what is the maximum possible time that
this patient would have been able to wait before being
seen?” with options of “patient could not wait”, 10 minutes,
30 minutes, 90 minutes, or “no emergency”. To further
standardize the adjudication, we developed examples prior
to the start of this study, which were distributed to adjudi-
cators. In case of disagreement, a third independent phys-
ician reviewed the case until consensus was reached
among the three. We then dichotomized the initial five
priority categories into two categories (i.e., low priority
[more than 10 minutes, class 3, 4 or 5] versus high priority
[less than 10 minutes, class 1 or 2]).
Definitions of diagnoses and main symptoms at ED
admission
Based on the information available at ED discharge,
patients were grouped into different main diagnoses
(infection, gastrointestinal disease, cardiovascular disease,
worsening of general condition, neurological disease, other
disease) and symptom categories (general malaise, pain,
gastrointestinal symptom, neurological symptom, fever,
respiratory symptom). Thereby, the group of “neurological
symptoms” included reduced consciousness, dizziness,
confusion, syncope or the state shortly after, and neuro-
logical deficits.
Blood draws and candidate biomarkers
Leftover blood samples of routinely collect blood tubes
on admission were immediately centrifuged, aliquoted
and frozen at −20 °C for later batch analysis of blood
biomarkers. The results of these analyses were not avail-
able at the time of hospitalization of the patients and,
thus, physicians, patients and outcome adjudicators were
blinded to their results. We decided to examine blood
markers from three different distinct biologic pathways
as candidate biomarkers, namely inflammation (ProADM)
[13–19], stress (copeptin) [19–23] and bacterial infection
(PCT) [24–27] based on the previous literature demonstrat-
ing a high prognostic potential of these markers. ProADM
and copeptin were batch-measured in plasma with a new
sandwich immunoassay as described elsewhere [32–34].
The assays have analytical detection limits of 0.08 nmol/L
and 0.4 pmol/L, respectively. PCT was measured with a
highly sensitive time-resolved amplified cryptate emission
(TRACE) technology assay (PCT Kryptor®, B.R.A.H.M.S.
AG, Hennigsdorf, Germany). The assay has a detection
limit of 0.02 ug/L and functional assay sensitivity of
0.06 μg/L.
Statistical considerations and sample size
We aimed to include a total of at least 7000 patients
with expected rates for mortality of 5 % (n = 350), ICU
admission of 7 % (n = 490) and high treatment priority
of 40 % (n = 2800). This provides 35–280 degrees of free-
dom for each model (with ten outcome in the data set
per degree of freedom in the statistical model), and thus
high power for the calculation of the main multivariate
models overall and in predefined subgroups.
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We used multivariable logistic regression models to
examine the association of biomarker levels with the pri-
mary and the two secondary endpoints. The distribution of
raw biomarker data was skewed. After log transformation
with a base of ten, the distribution of the biomarker data
approximated a normal distribution. We report odds ratios
(ORs) and 95 % confidence intervals (CIs) as a measure of
association and C-statistics (area under the curve [AUC])
as a measure of discrimination. ORs thereby correspond to
a one-unit increase in the explanatory variable and to any
tenfold increase in log-transformed biomarker levels (log
transformed with a base of ten). As predefined, regression
models were adjusted for age and gender (model 1),
age, gender, comorbidities, main symptom, main diagnosis
(model 2), and for age, gender, comorbidities, main symp-
tom, main diagnosis, vital signs (model 3). To assess the
incremental usefulness of one or all biomarker levels to
the clinical information available at ED admission, we per-
formed a head-to-head comparison between statistical
models limited to clinical information and models with
clinical and biomarker information. For this analysis we
predefined the clinical models as “initial clinical model”
(including only information available at ED admission
such as age, gender, main presenting symptom and vital
signs), “full clinical model” (including all clinical parameters
available at ED discharge such as age, gender, comorbidi-
ties, main presenting symptom, main diagnosis and vital
signs); and “triage scores models” (including the triage score
(one to five triage classes) as assessed in the emergency de-
partment). For nested model comparisons, we used the
likelihood ratio test as recommended [35]. Finally, we also
investigated subgroups for differences in performance
between centers, main diagnoses, main symptoms and
sociodemographic factors (age).
The effects of adding ProADM to clinical information
were further assessed using reclassification methods [36].
The analyses used continuous variable information with
evaluation of the effects on risk category reclassification
for all three endpoints. This approach separately analyzed
the reclassification of persons who did or did not reach
the outcome of interest. Reclassification to a higher risk
group was considered upward movement in classification
for participants not reaching the endpoint. On the other
hand, reclassification downward was considered a failure
for participants reaching the endpoint. We used risk cat-
egories of 5 and 10 % for mortality and ICU admission,
and 20 and 50 % for triage priority. We calculated the net
reclassification improvement (NRI), which assesses im-
provement in reclassification over risk categories; we also
assessed integrated discrimination improvement (IDI),
which can be viewed as a continuous version of the NRI
without the recourse to a priori defined risk categories.
Discrete variables are expressed as frequency (percentage)
and continuous variables as means and standard deviations
(SDs) or medians and interquartile ranges (IQRs). Analyses




A total of 7342 patients were included in the ED of the
participating Swiss, US and French hospitals of whom 7132
patients had follow-up information and were included in
the final analysis (n = 4579, n = 1000 and n = 1553). A de-
tailed flow diagram is displayed in the Appendix. The me-
dian age was 62 years and 46.7 % of patients were females.
The most frequent main complaints at ED admission were
neurological symptoms (19.3 %), nonthoracic (17.1 %) and
thoracic (14.6 %) pain and respiratory symptoms (13.3 %).
The most prevalent main diagnoses were cardiovascular
diseases (24.3 %), neurological diseases (22.0 %) and infec-
tions (12.6 %). Patients had a high burden of comorbidities
including hypertension (39.2 %), coronary heart disease
(11.7 %). diabetes (15.3 %) and cancer (13.6 %). Most pa-
tients were treated as inpatients (72.8 %) with a mean
length of stay (LOS) of 6.0 days and variability among trial
sites (range 38.4–100 %). Overall, 46.0 % of patients were
adjudicated as having a high initial treatment priority. In re-
gard to adverse outcome within 30 days of ED admission,
6.4 % of patients were admitted to ICU, 2.6 % died in the
hospital and 4.6 % died within 30 day of admission. Add-
itional baseline and follow-up patient characteristics of the
overall population and stratified according to trial site are
presented in Table 1.
Association of initial blood markers and adverse outcome
In unadjusted logistic regression analysis, we found strong
associations of all three measured biomarkers (ProADM,
copeptin, PCT) and primary and secondary endpoints,
namely 30-day mortality, admission to ICU and high initial
treatment priority. These associations remained robust in
different multivariate models including age and gender
(model 1), age, gender, comorbidities, main symptom, main
diagnosis (model 2), and age, gender, comorbidities, main
symptom, main diagnosis, vital signs (model 3) (Table 2).
For mortality prediction, ProADM had the best discrimin-
ation value with an AUC of 0.83 compared to 0.78 for
copeptin and 0.75 for PCT. For prediction of ICU admis-
sion and high initial triage priority, ProADM and copeptin
had the best discrimination values as compared to PCT (an
AUC of ProADM 0.67 and 0.67, copeptin 0.69 and 0.66,
PCT 0.62 vs. 0.58, respectively).
Incremental value of ProADM and biomarker panel on
clinical information
To study whether ProADM or a multimarker panel
including all three biomarkers would improve risk
prediction of available clinical information, we calculated
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Table 1 Patient characteristics overall and according to study site
All patients Swiss US French
n = 7132 4579 1000 1553
Sociodemographics
Age, median (IQR) 62 (46, 76) 63 (47, 76) 69 (55, 81) 55 (38, 69)
Female gender, n (%) 3301 (46.7 %) 2046 (44.7 %) 500 (50.0 %) 755 (50.7 %)
Clinical presentation at ED admission, median (IQR)
Blood pressure diastolic (mmHg) 80 (70, 90) 81 (71, 91) 77.5 (67, 89) 79 (70, 90)
Blood pressure systolic (mmHg) 137 (121, 154) 138 (122, 155) 141 (121, 163) 133 (119, 149)
Confusion, n (%) 522 (7.3 %) 453 (9.9 %) 40 (4.0 %) 29 (1.9 %)
Pulse (bpm) 83 (71, 97) 82 (70, 95) 82 (71, 98) 86 (74, 99)
Respiratory rate (breaths/min) 18 (18, 20) 32 (24, 36) 18 (18, 20) 21 (18, 25)
SpO2 (%) 96.8 (94, 98) 96 (94, 97) 97 (95, 99) 98 (96, 99)
Temperature (°C), 36.8 (36.4, 37.2) 36.9 (36.6, 37.4) 36.5 (36.1, 36.8) 36.7 (36.4, 37)
Main symptom at ED admission, n (%)
Diarrhea, vomitus, dysuria 495 (6.9 %) 288 (6.3 %) 95 (9.5 %) 112 (7.2 %)
Fever 343 (4.8 %) 254 (5.5 %) 15 (1.5 %) 74 (4.8 %)
Gastrointestinal bleeding 199 (2.8 %) 140 (3.1 %) 28 (2.8 %) 31 (2.0 %)
Neurological symptoms 1379 (19.3 %) 1138 (24.9 %) 78 (7.8 %) 163 (10.5 %)
Nonthoracic pain 1217 (17.1 %) 682 (14.9 %) 103 (10.3 %) 432 (27.8 %)
Respiratory symptoms 948 (13.3 %) 526 (11.5 %) 220 (22.0 %) 202 (13.0 %)
Thoracic pain 1038 (14.6 %) 690 (15.1 %) 153 (15.3 %) 195 (12.6 %)
Worsening of general condition 837 (11.7 %) 258 (5.6 %) 308 (30.8 %) 271 (17.5 %)
Other symptom 676 (9.5 %) 603 (13.2 %) 0 (0.0 %) 73 (4.7 %)
Main diagnosis, n (%)
Cancer 297 (4.2 %) 234 (5.1 %) 29 (2.9 %) 34 (2.2 %)
Cardiovascular 1732 (24.3 %) 1003 (21.9 %) 413 (41.3 %) 316 (20.3 %)
Gastrointestinal 896 (12.6 %) 503 (11.0 %) 92 (9.2 %) 301 (19.4 %)
Infection 896 (12.6 %) 657 (14.3 %) 49 (4.9 %) 190 (12.2 %)
Metabolic 238 (3.3 %) 62 (1.4 %) 56 (5.6 %) 120 (7.7 %)
Neurological 1569 (22.0 %) 1150 (25.1 %) 160 (16.0 %) 259 (16.7 %)
Pulmonary 471 (6.6 %) 169 (3.7 %) 158 (15.8 %) 144 (9.3 %)
Other 1033 (14.5 %) 801 (17.5 %) 43 (4.3 %) 189 (12.2 %)
Comorbidities, n (%)
Cancer 968 (13.6 %) 678 (14.8 %) 79 (7.9 %) 211 (13.6 %)
Chronic renal failure 872 (12.2 %) 694 (15.2 %) 78 (7.8 %) 100 (6.4 %)
Congestive heart failure 487 (6.8 %) 286 (6.2 %) 118 (11.8 %) 83 (5.3 %)
COPD 359 (5.0 %) 229 (5.0 %) 51 (5.1 %) 79 (5.1 %)
Coronary heart disease 838 (11.7 %) 557 (12.2 %) 107 (10.7 %) 174 (11.2 %)
Dementia 223 (3.1 %) 147 (3.2 %) 67 (6.7 %) 9 (0.6 %)
Diabetes 1088 (15.3 %) 681 (14.9 %) 224 (22.4 %) 183 (11.8 %)
History of stroke 566 (7.9 %) 456 (10.0 %) 5 (0.5 %) 105 (6.8 %)
Hypertension 2795 (39.2 %) 1920 (41.9 %) 479 (47.9 %) 396 (25.5 %)
Substance abuse 460 (6.4 %) 303 (6.6 %) 52 (5.2 %) 105 (6.8 %)
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different regression models based on (a) clinical informa-
tion readily available at ED admission (age, gender, main
presenting symptom and vital signs), (b) full clinical infor-
mation available at ED discharge (age, gender, comorbidi-
ties, main presenting symptom, main diagnosis and vital
signs) and (c) information from initial triage scores
(Table 3 and Fig. 1). ProADM was found to substantially
improve all models with best improvements for prediction
of 30-day mortality (from AUC 0.79 to 0.84 for the model
including clinical information readily available at ED ad-
mission; from AUC 0.85 to 0.88 for the model including
full clinical information available at ED discharge; from
AUC 0.67 to 0.83 for the model including information
from initial triage scores. Compared to the model in-
cluding ProADM only, the multimarker panel (includ-
ing all three markers) provided only minimal additional
improvement of around 0.01 in the AUC. The results for
ICU admission and initial triage priority were similar with
significant improvements by addition of ProADM and
only minimal additional improvement with the multimar-
ker panel.
Improvements in risk assessment were also found in
reclassification statistics. Table 4 shows the results of net
reclassification improvement (NRI) across the three risk
categories and integrated discrimination improvement
(IDI) for continuous results. All models were significantly
improved by the addition of ProADM (reclassification ta-
bles are presented in the Appendix). Particularly, ProADM
increased the predicted risk of nonsurvivors in 14, 15 and
32 % in the different models. On the other hand, ProADM
lowered the predicted risk in patients not needing ICU
care by 10, 4 and 23 %.
Table 1 Patient characteristics overall and according to study site (Continued)
Initial blood biomarkers, median (IQR)
Copeptin, (pmol/L) 10.74 (4.54, 38.90) 11.60 (4.70, 43.80) 15.02 (5.70, 59.42) 7.63 (3.95, 19.21)
Creatinine (micromol/L) 81.0 (67.0, 103.0) 85.0 (70.0, 106.0) 79.6 (70.7, 106.1) 67.0 (55.0, 84.0)
Glucose (mmol/L) 6.1 (5.3, 7.5) 6.2 (5.4, 7.5) 6.3 (5.3, 8.2) 5.8 (5.2, 6.9)
Hemoglobin (G/L) 13.6 (12.1, 14.8) 13.7 (12.2, 14.9) 12.9 (11.4, 14.4) 13.7 (12.4, 14.8)
PCT (ug/L) 0.08 (0.06, 0.13) 0.08 (0.06, 0.13) 0.09 (0.06, 0.15) 0.08 (0.06, 0.13)
ProADM (nmol/L) 0.79 (0.57, 1.24) 0.81 (0.60, 1.27) 0.98 (0.70, 1.62) 0.59 (0.45, 0.88)
Sodium (mmol/L) 139 (137, 140) 139 (137, 141) 138 (136, 140) 138 (137, 140)
WBC (G/L) 8.4 (6.6, 10.9) 8.5 (6.7, 11.0) 8.3 (6.4, 11) 8.1 (6.3, 10.8)
Initial triage score, n (%)
No emergency 774 (11.1 %) 638 (14.2 %) 0 (0.0 %) 136 (9.1 %)
Within 90 minutes 1746 (25.1 %) 1030 (23.0 %) 61 (6.1 %) 655 (43.9 %)
Within 30 minutes 3030 (43.5 %) 1783 (39.8 %) 693 (69.3 %) 554 (37.2 %)
Within 10 minutes 1256 (18.0 %) 910 (20.3 %) 219 (21.9 %) 127 (8.5 %)
Immediate treatment needed 163 (2.3 %) 117 (2.6 %) 27 (2.7 %) 19 (1.3 %)
Patient outcomes, n (%)
Site of care, n (%)
Outpatient treatment 1555 (27.2 %) 637 (19.8 %) 0 (0.0 %) 918 (61.6 %)
Length of stay, mean (SD) 6.0 (6.1) 5.7 (5.1) 5.0 (5.3) 9.5 (9.5)
Location after hospital/ED discharge, n (%)
Home 5983 (83.9 %) 3796 (82.9 %) 723 (72.3 %) 1464 (94.3 %)
Other institution 504 (7.1 %) 435 (9.5 %) 61 (6.1 %) 8 (0.5 %)
Rehabilitation 320 (4.5 %) 207 (4.5 %) 50 (5.0 %) 63 (4.1 %)
Other 325 (4.6 %) 141 (3.1 %) 166 (16.6 %) 18 (1.2 %)
Outcomes within 30 days, n (%)
Intensive care unit admission 453 (6.4 %) 181 (4.0 %) 153 (15.3 %) 119 (7.7 %)
Inhospital mortality 188 (2.6 %) 136 (3.0 %) 21 (2.1 %) 31 (2.0 %)
30-day mortality 331 (4.6 %) 252 (5.5 %) 45 (4.5 %) 34 (2.2 %)
Unplanned hospital readmission 590 (8.3 %) 311 (6.8 %) 184 (18.4 %) 95 (6.1 %)
IQR interquartile range, ED emergency department, COPD chronic obstructive pulmonary disease, PCT procalcitonin, ProADM pro-adrenomedullin, WBC white blood
cell count, SD standard deviation
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Subgroup analysis
To study the robustness of our analysis across patient pop-
ulations, we also investigated the prognostic performance
of the markers for the three different outcomes in pre-
defined subgroup analyses according to study center
(Swiss, French, US), main medical diagnosis (infectious
disease, cardiovascular disease, neurological disease),
main symptom at ED presentation (nonthoracic pain,
thoracic pain, respiratory symptoms, worsening of general
condition, fever), age (<65 years, ≥65 years) and gender.
As shown in the Appendix, results were similar in the dif-
ferent subgroups with the best performance in the French
center, in patients with thoracic and nonthoracic pain,
in patients with fever and in younger patients (age
<65 years).
Discussion
Suboptimal triage causes delays in initial treatment and
impaired outcome [3, 4]. A more adequate and prompt
initial triage system usable in unselected, “real-life” ED
patients may allow for an improved and more targeted
(“personalized”) management of patients in the ED [12].
Within this large international cohort of unselected
medical patients seeking ED care, we investigated the in-
cremental usefulness of three biomarkers from distinct
biological pathways for predicting short-term mortality,
Table 2 Association of biomarkers with primary and secondary outcomes
ProADM (nmol/L) Copeptin (pmol/L) Procalcitonin (ug/L)
30-day mortality
Survivors, median (IQR) 0.8 (0.6 to 1.2) 10 (4 to 35) 0.08 (0.05 to 0.13)
Nonsurvivors, median (IQR) 1.8 (1.1 to 3.9) 62 (22 to 154) 0.17 (0.09 to 0.50)
Regression analysis, OR (95 % CI)
Unadjusted model 32.3 (23.1, 45.2) 4.3 (3.6, 5.1) 2.7 (2.4, 3.2)
Multivariate model 1 20.4 (14.1, 29.4) 3.4 (2.8, 4) 2.5 (2.1, 2.9)
Multivariate model 2 22.4 (14.4, 34.9) 3.5 (2.8, 4.3) 2.5 (2.1, 3)
Multivariate model 3 21.4 (13.5, 34) 3.2 (2.6, 4) 2.4 (2, 2.9)
Discrimination statistics
AUC (95 % CI) 0.83 (0.81, 0.85) 0.78 (0.75, 0.80) 0.75 (0.72, 0.77)
Admission to ICU
No admission to ICU, median (IQR) 0.8 (0.6 to 1.2) 10 (5 to 35) 0.08 (0.06 to 0.13)
Admission to ICU, median (IQR) 1.2 (0.7 to 2.3) 41 (10 to 138) 0.10 (0.07 to 0.26)
Regression analysis, OR (95 % CI)
Unadjusted model 7.7 (5.8, 10.3) 3 (2.6, 3.4) 1.9 (1.6, 2.1)
Multivariate model 1 8 (5.8, 11) 2.9 (2.5, 3.4) 1.7 (1.5, 2)
Multivariate model 2 10 (6.9, 14.5) 3 (2.6, 3.6) 2.1 (1.8, 2.5)
Multivariate model 3 7.7 (5.2, 11.5) 2.8 (2.4, 3.3) 1.9 (1.6, 2.3)
Discrimination statistics
AUC (95 % CI) 0.67 (0.65, 0.70) 0.69 (0.67, 0.72) 0.62 (0.59, 0.64)
High initial triage priority
Low triage priority, median (IQR) 0.7 (0.5 to 1.0) 8 (4 to 21) 0.07 (0.06 to 0.11)
High triage priority, median (IQR) 1.0 (0.7 to 1.6) 18 (6 to 68) 0.08 (0.06 to 0.16)
Regression analysis, OR (95 % CI)
Unadjusted model 10 (8.2, 12.2) 2.6 (2.4, 2.8) 1.9 (1.7, 2.1)
Multivariate model 1 8.6 (6.8, 10.8) 2.2 (2, 2.4) 1.6 (1.5, 1.8)
Multivariate model 2 11.6 (8.8, 15.2) 2.3 (2.1, 2.6) 1.7 (1.5, 1.9)
Multivariate model 3 10.8 (8.2, 14.3) 2.2 (2, 2.5) 1.6 (1.4, 1.8)
Discrimination statistics
AUC (95 % CI) 0.67 (0.66, 0.68) 0.66 (0.65, 0.67) 0.58 (0.56, 0.59)
Biomarker data were log transformed before entering into the statistical models with a base of ten. The ORs therefore correspond to a tenfold increase in
biomarker levels. Model 1 (age, gender), model 2 (age, gender, comorbidities, main symptom, main diagnosis), model 3 (age, gender, comorbidities, main
symptom, main diagnosis, vital signs)
ProADM pro-adrenomedullin, IQR interquartile range, OR odds ratio, CI confidence interval, AUC area under the curve
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ICU admission and high triage priority. ProADM emerged
as the most informative biomarker for predicting adverse
outcomes with high discriminatory ability particularly in
regard to the primary endpoint – all-cause 30-day mortal-
ity. In addition, the use of ProADM added to the overall
prediction of risk based on clinical parameters available on
ED admission and ED discharge, as well as triage informa-
tion. The addition of all three biomarkers in a “multimar-
ker” model showed only minimal further improvements, as
evidenced by small changes in the C-statistic. These results
suggest that a combined clinical and biomarker approach
may help to accurately risk stratify patients at the most
proximal and challenging time point of ED admission.
Risk prediction may also assist physicians in more ra-
tional decision making regarding initial site-of-care with
implications for the entire hospitalization. Reducing the
number of inhospital days is important not only for cost
issues [37, 38]. Hospital-acquired disability is an emer-
ging issue in health care and older, frail medical patients
are at high risk for allegedly premature referral to a
nursing home with consecutive depression and further
deterioration of mental and physical independence [39].
This may help to identify both high-risk patients in need
of urgent care and inhospital management and low-risk
patients where longer waiting times have no detrimental
consequences.
Our data show large improvements in risk prediction
for all outcomes when ProADM is added to the clinical
risk model as evidenced by significant improvement in
AUCs with best performance in the initial triage model
and the initial clinical model. Particularly for identifica-
tion of patients at increased risk for 30-day mortality,
ProADM was most helpful. Conversely, for assessment
of triage priority, ProADM improved identification of
low-risk subjects, which may help to “rule out” the need
for immediate medical measures. Based on these results,
it is tempting to hypothesize that an initial assessment in-
cluding clinical and biomarker information will improve
risk stratification of patients, which may translate into bet-
ter patient flow and outcomes. Still, when looking at the
reclassification statistics when looking at the reclassicia-
tion statistics of the final overall clinical model, improve-
ments were only modest across risk categories and it thus
remains unclear how many patients would benefit from
biomarker testing if used in clinical practice. Thus, there is
need for verification of our hypothesis in an interventional
trial.
Indeed, to improve hospital management of patients
with lower respiratory tract infections, we have previ-
ously developed a biomarker-enhanced clinical risk score
(combining the CURB65 score and ProADM) [18, 40].
The efficacy and safety of this score was recently tested
in a randomized controlled trial at one of the participat-
ing hospitals [41]. Based on these studies focusing on re-
spiratory infections, we hypothesized that combining
clinical parameters and prognostic biomarkers to an
established triage risk score at the very proximal time
point of ED admission, also has a substantial and clinic-
ally relevant potential to improve its performance and
translate into better triage of unselected medical patients
on admission and during hospitalization.
While prognostic markers have been found in different
patient populations, only few investigations have found
improvement in care based on the incorporation of prog-
nostic information into “real-life” management of unse-
lected polymorbid medical patients. To our knowledge, no
Table 3 Prediction of adverse outcome of clinical models, biomarkers and combinations
Mortality ICU admission High treatment priority
AUC (95 % CI) p value AUC (95 % CI) p value AUC (95 % CI) p value
Models including clinical information readily available at ED admission
Initial clinical model 0.79 (0.77, 0.81) - 0.70 (0.67, 0.72) - 0.71 (0.70, 0.72) -
Initial clinical model plus ProADM 0.84 (0.83, 0.86) <0.001 0.73 (0.70, 0.75) <0.001 0.74 (0.73, 0.76) <0.001
Initial clinical model plus multimarker 0.85 (0.83, 0.87) <0.001 0.75 (0.73, 0.77) <0.001 0.75 (0.74, 0.76) <0.001
Models including full clinical information available at ED discharge
Full clinical model 0.85 (0.83, 0.87) - 0.75 (0.72, 0.77) - 0.73 (0.72, 0.74) -
Full clinical model plus ProADM 0.88 (0.87, 0.90) <0.001 0.77 (0.75, 0.79) <0.001 0.76 (0.75, 0.77) <0.001
Full clinical model plus multimarker 0.89 (0.88, 0.91) <0.001 0.79 (0.77, 0.81) <0.001 0.77 (0.75, 0.78) <0.001
Models including information from initial triage scores
Triage model 0.67 (0.64, 0.70) - 0.73 (0.72, 0.74) - 0.79 (0.77, 0.81) -
Triage model plus ProADM 0.83 (0.81, 0.85) <0.001 0.76 (0.75, 0.77) <0.001 0.84 (0.83, 0.86) <0.001
Triage model plus multimarker 0.84 (0.82, 0.86) <0.001 0.77 (0.75, 0.78) <0.001 0.85 (0.83, 0.87) <0.001
Initial clinical model includes age, gender, main presenting symptom and vital signs (i.e., heart rate, respiratory rate, blood pressure, temperature, consciousness);
full clinical model includes age, gender, comorbidities, main presenting symptom, main diagnosis and vital signs; multimarker model includes ProADM,
procalcitonin, copeptin; p value refers to comparison of combined model with the clinical model
ICU intensive care unit, AUC area under the curve, CI confidence interval, ED emergency department, ProADM pro-adrenomedullin
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study has yet investigated prognostic markers for early tri-
age, which can reduce time to treatment – a main pre-
dictor for patient outcomes. Indeed, the robustness of our
observational findings in different settings, health care sys-
tems and medical patient populations in situations of
diagnostic ambiguities can be seen as a strength of this
study.
We are aware of several limitations. First, treatment
priority as adjudicated by two independent attending
physicians at ED discharge is not a “hard” endpoint and
may be subject to variation due to different levels of ex-
perience of physicians. In anticipation of this limitation,
we have developed guidelines to standardize adjudication
based on previous research in this field [42]. We therefore
used triage priority as a secondary endpoint and also fo-
cused on other more objective endpoints (i.e., mortality,
ICU admission). Second, physicians and nurses were not
blinded to the triage scores and thus may adapt their pri-
ority recommendation accordingly. This may overestimate
the performance of the triage scoring systems. Third, we
only focused on three markers based on their performance
in previous research, but other markers such as lactate or
C-reactive protein (CRP) may also show benefit for early
patient triage [43]. Fourth, within this observational co-
hort, we are not able to demonstrate whether improved
triage of patients translates into better management and
improved outcomes; for this reason, a randomized con-
trolled trial ultimately testing this hypothesis needs to be
done. While most prognostic blood markers (including
ProADM) are now commercially available within 1 to
3 hours, faster point-of-care tests are currently being
Fig. 1 Receiver operating characteristic (ROC) analysis comparing
three models for prediction of outcomes: a clinical model (a), a
biomarker model (b) and a clinical plus biomarker model (c)
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signs (i.e., heart rate, respiratory rate, blood pressure, temperature, consciousness);
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developed that will enable measurement of markers within
minutes, similar to a glucose measurement [44]. This will
further improve bedside use of these markers in future tri-
als. Finally, due to differences in health care systems and
logistics at the ED, the cohorts were somewhat heteroge-
neous in the participating centers with differences in rates
of adverse outcomes and outpatient treatment (e.g., out-
patient rate in the Swiss 19.8 %, French: 61.6 % and US
center: 0 %). However, the robust results when looking at
the prognostic accuracy of markers among the different
centers is reassuring and may validate the findings for
these different health care settings.
Conclusions
In conclusion, combination of clinical information at ED
admission with results of blood biomarkers allows early
risk stratification in individual patients. The potential of
early triage to improve patient flow, treatment times,
medical outcomes and costs needs to be assessed in a
randomized interventional trial. In light of the current
discussion about limited health care resources, such a
trial will have high relevance for our health care system.
Key messages
 This large international emergency department
study found a high prognostic accuracy of initially
measured biomarkers for prediction of adverse
outcome and high treatment priority
 Biomarkers improved statistical models, including
comprehensive clinical information as well as triage
risk scores
 The best biomarker was ProADM, particularly for
mortality prediction
 Biomarker-enhanced patient triage in the emergency
department has the potential to improve early
patient management, patient flow and maybe also
reduce adverse outcomes
Abbreviations
ATS: Australasian Triage Scale; AUC: area under the curve; CAP: community-
acquired pneumonia; CI: confidence interval; COPD: chronic obstructive
pulmonary disease; CRF: case report form; CRP: C-reactive protein;
CTAS: Canadian Triage and Acuity Scale; ED: emergency department;
ESI: Emergency Severity Index; ICU: intensive care unit; IDI: integrated
discrimination improvement; IQR: interquartile range; LOS: length of stay;
MTS: Manchester Triage System; NRI: net reclassification improvement;
OR: odds ratio; PCT: procalcitonin; ProADM: pro-adrenomedullin;
PSI: Pneumonia Severity Index; SD: standard deviation; SE: standard error;
WBC: white blood cell count.
Competing interests
PS, AK and BM received support from B · R · A · H · M · S AG (now Thermo
Fisher Scientific Biomarkers) and bioMérieux to attend meetings and fulfill
speaking engagements and received research grants from these two firms,
and BM has served as a consultant to both companies. PH received research
grants and support from Thermo Fisher Scientific BRAHMS to attend
meetings and fulfill speaking engagements. All other authors have no
conflicts of interest relevant to this study.
Authors’ contributions
All authors contributed to conception and design. PS, PH, DA, SH, AK, and
BM contributed to analysis and interpretation. All authors contributed to
drafting the manuscript for important intellectual content. All authors read
and approved the manuscript.
Acknowledgements
This multidisciplinary and interprofessional trial was only possible in close
collaboration of social services (Anja Keller, Regina Schmid), the nursing
department (Susanne Schirlo, Petra Tobias), the central laboratory (Martha
Kaeslin, Renate Hunziker), medical controlling (Juergen Froehlich, Thomas
Holler, Christoph Reemts), IT (Roger Wohler, Kurt Amstad, Ralph Dahnke,
Sabine Storost) of the Kantonsspital Aarau, Clinical Trial Unit (CTU), University
Hospital Basel (Thomas Fabbro, Guido Stirnimann, Patrick Simon), the
department of Health Economics of the University of Basel (Stefan Felder,
Timo Tondelli), as well as all participating patients, nurses and physicians.
This study was supported by the Schweizerische Akademie der
Medizinischen Wissenschaften (SAMW). Thermofisher provided an
unrestricted research grant for this study. PS is supported by the Swiss
National Science Foundation (SNSF Professorship, PP00P3_150531/1).
The TRIAGE study group includes members from the University Department
of Internal Medicine, Kantonsspital Aarau, Switzerland (Ulrich Buergi, MD,
Petra Tobias, RN, Eva Grolimund, MD, Ursula Schild, RN, Zeljka Caldara, RN,
Katharina Regez, RN, Martha Kaeslin, Ursina Minder, RN, Renate Hunziker, RN,
Andriy Zhydkov, MD, Timo Kahles, MD, Krassen Nedeltchev, MD, Petra
Schäfer-Keller, PhD) the Clinical Trial Unit University Hospital Basel (Stefanie
von Felten, PhD), the Institute of Nursing Science, University of Basel,
Switzerland (Sabina De Geest, PhD); the Department of Psychology, University
of Berne (Pasqualina Perrig-Chiello, PhD); Department of Emergency Medicine,
Hôpital Pitié-Salpétriêre, Paris, France; (Anne-Laure Philippon, David Pariente,
Jérome Bokobza, Adeline Aubry, Nadia De Tommaso, Ilaria Cherubini, Aline
Lecocq, Kahina Kachetel); the Morton Plant Hospital, Clearwater, FL, USA
(Rebecca Virgil, RN, Jo Simpson, RN).
Funding information
Thermofisher provided an unrestricted research grant for this study. PS is
supported by the Swiss National Science Foundation (SNSF Professorship,
PP00P3_150531/1). This study was supported by the Schweizerische
Akademie der Medizinischen Wissenschaften (SAMW).
Author details
1Division of General and Emergency Medicine, University Department of
Medicine, Kantonsspital Aarau, Tellstrasse, 5001 Aarau, Switzerland.
2Emergency Department, Groupe Hospitalier Pitié-Salpêtrière Assistance
Publique-Hôpitaux de Paris (APHP), Paris, France. 3Department of critical care,
Morton Plant Hospital, 300 Pinellas Street, Clearwater, FL 33756, USA.
4Department of Clinical Nursing Science, Kantonsspital Aarau, Tellstrasse,
5001 Aarau, Switzerland. 5Department of Laboratory Medicine, Kantonsspital
Aarau, Tellstrasse, 5001 Aarau, Switzerland. 6Medical Faculty of the University
of Basel, Basel, Switzerland. 7Biochemistry Department, Hôpital
Pitié-Salpêtrière and Univ-Paris Descartes, Paris, France.
Received: 18 September 2015 Accepted: 10 October 2015
References
1. Burt CW, McCaig LF, Rechtsteiner EA. Ambulatory medical care utilization
estimates for. Adv Data. 2007;2005:1–15.
2. McCaig LF, Burt CW. National Hospital Ambulatory Medical Care Survey:
2002 emergency department summary. Adv Data. 2004;2002:1–34.
3. Guttmann A, Schull MJ, Vermeulen MJ, Stukel TA. Association between
waiting times and short term mortality and hospital admission after
departure from emergency department: population based cohort study
from Ontario. Canada BMJ. 2011;342:d2983.
4. Sun BC, Hsia RY, Weiss RE, Zingmond D, Liang LJ, Han W, et al. Effect of
emergency department crowding on outcomes of admitted patients. Ann
Emerg Med. 2013;61:605–11.
5. Puskarich MA, Trzeciak S, Shapiro NI, Heffner AC, Kline JA, Jones AE, et al.
Outcomes of patients undergoing early sepsis resuscitation for cryptic shock
compared with overt shock. Resuscitation. 2011;82:1289–93.
Schuetz et al. Critical Care  (2015) 19:377 Page 10 of 11
6. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration
of hypotension before initiation of effective antimicrobial therapy is the
critical determinant of survival in human septic shock. Crit Care Med.
2006;34:1589–96.
7. Adams Jr HP, Effron MB, Torner J, Davalos A, Frayne J, Teal P, et al.
Emergency administration of abciximab for treatment of patients with acute
ischemic stroke: results of an international phase III trial: Abciximab in
Emergency Treatment of Stroke Trial (AbESTT-II). Stroke. 2008;39:87–99.
8. Cantor WJ, Fitchett D, Borgundvaag B, Ducas J, Heffernan M, Cohen EA, et
al. Routine early angioplasty after fibrinolysis for acute myocardial infarction.
N Engl J Med. 2009;360:2705–18.
9. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A
prediction rule to identify low-risk patients with community-acquired
pneumonia. N Engl J Med. 1997;336:243–50.
10. Christ M, Grossmann F, Winter D, Bingisser R, Platz E. Modern triage in the
emergency department. Dtsch Arztebl Int. 2010;107:892–8.
11. Grossmann FF, Nickel CH, Christ M, Schneider K, Spirig R, Bingisser R.
Transporting clinical tools to new settings: cultural adaptation and validation of
the Emergency Severity Index in German. Ann Emerg Med. 2011;57:257–64.
12. Schuetz P, Aujesky D, Muller C, Muller B. Biomarker-guided personalised
emergency medicine for all - hope for another hype? Swiss Med Wkly.
2015;145:w14079.
13. Schuetz P, Marlowe RJ, Mueller B. The prognostic blood biomarker
proadrenomedullin for outcome prediction in patients with chronic
obstructive pulmonary disease (COPD): a qualitative clinical review. Clin
Chem Lab Med. 2015;53:521–39.
14. Henriquez-Camacho C, Losa J. Biomarkers for sepsis. Biomed Res Int.
2014;2014:547818.
15. Suberviola B, Castellanos-Ortega A, Ruiz Ruiz A, Lopez-Hoyos M, Santibanez
M. Hospital mortality prognostication in sepsis using the new biomarkers
suPAR and proADM in a single determination on ICU admission. Intensive
Care Med. 2013;39:1945–52.
16. Courtais C, Kuster N, Dupuy AM, Folschveiller M, Jreige R, Bargnoux AS, et al.
Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity
Index score community acquired pneumonia. Am J Emerg Med. 2013;31:215–21.
17. Bello S, Lasierra AB, Minchole E, Fandos S, Ruiz MA, Vera E, et al. Prognostic
power of proadrenomedullin in community-acquired pneumonia is
independent of aetiology. Eur Respir J. 2012;39:1144–55.
18. Albrich WC, Dusemund F, Ruegger K, Christ-Crain M, Zimmerli W, Bregenzer
T, et al. Enhancement of CURB65 score with proadrenomedullin (CURB65-A)
for outcome prediction in lower respiratory tract infections: derivation of a
clinical algorithm. BMC Infect Dis. 2011;11:112.
19. Schuetz P, Wolbers M, Christ-Crain M, Thomann R, Falconnier C, Widmer I,
et al. Prohormones for prediction of adverse medical outcome in
community-acquired pneumonia and lower respiratory tract infections. Crit
Care. 2010;14:R106.
20. De Marchis GM, Katan M, Weck A, Fluri F, Foerch C, Findling O, et al.
Copeptin adds prognostic information after ischemic stroke: results from
the CoRisk study. Neurology. 2013;80:1278–86.
21. Ostadal P, Kruger A, Zdrahalova V, Janotka M, Vondrakova D, Neuzil P, et al. Blood
levels of copeptin on admission predict outcomes in out-of-hospital cardiac
arrest survivors treated with therapeutic hypothermia. Crit Care. 2012;16:R187.
22. Potocki M, Breidthardt T, Mueller A, Reichlin T, Socrates T, Arenja N, et al.
Copeptin and risk stratification in patients with acute dyspnea. Crit Care.
2010;14:R213.
23. Kruger S, Ewig S, Giersdorf S, Hartmann O, Suttorp N, Welte T.
Cardiovascular and inflammatory biomarkers to predict short- and long-
term survival in community-acquired pneumonia. Am J Respir Crit Care
Med. 2010;182:1426–34.
24. Zhydkov A, Christ-Crain M, Thomann R, Hoess C, Henzen C, Werner Z, et al.
Utility of procalcitonin, C-reactive protein and white blood cells alone and
in combination for the prediction of clinical outcomes in community-
acquired pneumonia. Clin Chem Lab Med. 2015;53:559–66.
25. Garnacho-Montero J, Huici-Moreno MJ, Gutierrez-Pizarraya A, Lopez I,
Marquez-Vacaro JA, Macher H, et al. Prognostic and diagnostic value of
eosinopenia, C-reactive protein, procalcitonin, and circulating cell-free DNA in
critically Ill patients admitted with suspicion of sepsis. Crit Care. 2014;18:R116.
26. Schuetz P, Maurer P, Punjabi V, Desai A, Amin DN, Gluck E. Procalcitonin
decrease over 72 hours in US critical care units predicts fatal outcome in
sepsis patients. Crit Care. 2013;17:R115.
27. Hottenrott S, Schummer W. Value of procalcitonin as an outcome-parameter
after cardiac arrest. Resuscitation. 2013;84:e25–6.
28. Optimizing triage and hospitalisation in adult general medical emergency
patients: the TRIAGE Study. http://www.clinicaltrials.gov/ct2/show/
NCT01768494. Accessed on 10 Dec 2014.
29. Schuetz P, Hausfater P, Amin D, Haubitz S, Fassler L, Grolimund E, et al.
Optimizing triage and hospitalization in adult general medical emergency
patients: the triage project. BMC Emerg Med. 2013;13:12.
30. Steiner D, Renetseder F, Kutz A, Faessler L, Rast AC, Felder S, et al. Procalcitonin
for diagnosis of infection and guide to antibiotic decisions: past, present and
future J Emerg Med 2015 Oct 9. doi:10.1016/j.jemermed.2015.09.008.
31. Taboulet P, Moreira V, Haas L, Porcher R, Braganca A, Fontaine JP, et al.
Triage with the French Emergency Nurses Classification in Hospital scale:
reliability and validity. Eur J Emerg Med. 2009;16:61–7.
32. Morgenthaler NG, Muller B, Struck J, Bergmann A, Redl H, Christ-Crain M.
Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated
in hemorrhagic and septic shock. Shock. 2007;28:219–26.
33. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of
midregional proadrenomedullin in plasma with an immunoluminometric
assay. Clin Chem. 2005;51:1823–9.
34. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the
measurement of copeptin, a stable peptide derived from the precursor of
vasopressin. Clin Chem. 2006;52:112–9.
35. Vickers AJ, Cronin AM, Begg CB. One statistical test is sufficient for assessing
new predictive markers. BMC Med Res Methodol. 2011;11:13.
36. Pencina MJ, D’Agostino Sr RB, D’Agostino Jr RB, Vasan RS. Evaluating the
added predictive ability of a new marker: from area under the ROC curve to
reclassification and beyond. Stat Med. 2008;27:157–72. discussion 207–112.
37. Schuetz P, Albrich WC, Suter I, Hug BL, Christ-Crain M, Holler T, et al. Quality
of care delivered by fee-for-service and DRG hospitals in Switzerland in
patients with community-acquired pneumonia. Swiss Med Wkly.
2011;141:w13228.
38. Suter-Widmer I, Christ-Crain M, Zimmerli W, Albrich W, Mueller B, Schuetz P,
et al. Predictors for length of hospital stay in patients with community-
acquired pneumonia: results from a Swiss multicenter study. BMC Pulm
Med. 2012;12:21.
39. Covinsky KE, Pierluissi E, Johnston CB. Hospitalization-associated disability:
“She was probably able to ambulate, but I’m not sure”. JAMA. 2011;306:1782–93.
40. Albrich WC, Ruegger K, Dusemund F, Bossart R, Regez K, Schild U, et al.
Optimised patient transfer using an innovative multidisciplinary assessment
in Kanton Aargau (OPTIMA I): an observational survey in lower respiratory
tract infections. Swiss Med Wkly. 2011;141:w13237.
41. Albrich WC, Ruegger K, Dusemund F, Schuetz P, Arici B, Litke A, et al.
Biomarker-enhanced triage in respiratory infections: a proof-of-concept
feasibility trial. Eur Respir J. 2013;42:1064–75.
42. Storm-Versloot MN, Ubbink DT, Kappelhof J, Luitse JS. Comparison of an
informally structured triage system, the emergency severity index, and the
Manchester triage system to distinguish patient priority in the emergency
department. Acad Emerg Med. 2011;18:822–9.
43. Nickler M, Ottiger M, Steuer C, Huber A, Anderson JB, Muller B, Schuetz P.
Systematic review regarding metabolic profiling for improved
pathophysiological understanding of disease and outcome prediction in
respiratory infections. Respir Res. 2015;16:125.
44. Kutz A, Hausfater P, Oppert M, Alan M, Grolimund E, Gast C, et al.
Comparison between B.R.A.H.M.S PCT direct, a new sensitive point-of-care
testing device for rapid quantification of procalcitonin in emergency
department patients, and established reference methods - a prospective
multinational trial. Clin Chem Lab Med 2015. doi:10.1515/cclm-2015-0437.
Schuetz et al. Critical Care  (2015) 19:377 Page 11 of 11
